ResMed (RMD)
(Delayed Data from NYSE)
$197.04 USD
-11.30 (-5.42%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $197.20 +0.16 (0.08%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
ResMed (RMD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$214.67 | $238.00 | $180.00 | 3.04% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for ResMed comes to $214.67. The forecasts range from a low of $180.00 to a high of $238.00. The average price target represents an increase of 3.04% from the last closing price of $208.34.
Analyst Price Targets (9 )
Broker Rating
ResMed currently has an average brokerage recommendation (ABR) of 2.04 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 1.96 a month ago based on 14 recommendations.
Of the 13 recommendations deriving the current ABR, five are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 38.46% and 15.38% of all recommendations. A month ago, Strong Buy made up 42.86%, while Buy represented 14.29%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 6 | 6 | 8 | 8 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 6 | 6 | 6 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.04 | 1.96 | 1.96 | 1.68 | 1.68 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/25/2024 | Not Identified | Not Identified | Strong Buy | Hold |
6/24/2024 | Not Identified | Not Identified | Strong Buy | Hold |
4/26/2024 | KeyBanc Capital Markets | Brett Fishbin | Strong Buy | Strong Buy |
4/26/2024 | Not Identified | Not Identified | Hold | Hold |
4/25/2024 | Not Identified | Not Identified | Hold | Hold |
4/1/2024 | Needham & Company | Michael Matson | Moderate Buy | Moderate Buy |
3/27/2024 | Mizuho SecuritiesUSA | Anthony Petrone | Strong Buy | Strong Buy |
1/29/2024 | William Blair | Margaret Kaczor | Strong Buy | Strong Buy |
1/26/2024 | UBS | Laura Sutcliffe | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.04 |
ABR (Last week) | 1.96 |
# of Recs in ABR | 13 |
Average Target Price | $214.67 |
LT Growth Rate | 13.30% |
Industry | Medical - Products |
Industry Rank by ABR | 93 of 252 |
Current Quarter EPS Est: | 2.04 |